Added to YB: 2025-08-11
Pitch date: 2025-08-08
HROW [bullish]
Harrow, Inc.
+1.41%
current return
Author Info
No bio for this author
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Market Cap
$1.3B
Pitch Price
$34.64
Price Target
100.00 (+185%)
Dividend
N/A
EV/EBITDA
29.74
P/E
-253.44
EV/Sales
5.49
Sector
Pharmaceuticals
Category
growth
Actionable Stock Set-up 7: Harrow Inc (HROW)
HROW: Ophthalmic pharma co w/ rapidly growing VEVYE (8x YOY, targeting $100M+ 2024 rev). Bull: aging population, strong pipeline, strategic acquisitions, mgmt aligned w/ $100 stock target. Bear: heavy debt ($230M), execution risk, high competition. Trading at 6.5x EV/S, 30x NTM P/E but only 8x 2027E.
Read full article (6 min)